Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

CARIPRAZINE

All products: general benefit

Other products in the same Health Canada class (N05A, N05AX) — coverage varies; not interchangeable

  • Aripiprazole (Abilify Asimtufii): general benefit
  • Brexpiprazole (Rexulti): general benefit
  • Paliperidone (Invega): general benefit
  • Paliperidone palmitate (Invega Sustenna): general benefit
  • Risperidone (Risperdal): general benefit, Not a benefit
  • Asenapine (Saphris): general benefit

18 more in the class list below

Vraylar · DIN 02526824 · 6mg · capsule

General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Vraylar · DIN 02526824 Manufacturer: AbbVie Corporation; listing date 2024-10-31 Health Canada: Marketed since 2024-02-08 · brand VRAYLAR · ATC N05AX15 CARIPRAZINE · form Capsule · route Oral · ingredients CARIPRAZINE (CARIPRAZINE HYDROCHLORIDE) 6 MG · company Abbvie corporation · schedule Prescription
Check this DIN again · Health Canada product record

Vraylar: Formulary list price $5.0960/unit (unit not stated in source; not the patient's cost)

Ministry pays: $5.0960 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101588 · Verify on the e-Formulary ↗ (DIN 02526824)

Source record
DIN 02526824: Vraylar Raw flags: sec3=Y Item: 281608359; group id 482; item number 1230; lccId None; manufacturer id ABV Source form: Cap; strength: 6mg Recorded listing: General benefit Source prices (unrounded): $5.0960; ministry $5.0960 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02526824 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101588
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (28:16:08 Tranquilizers) and how they are covered

Matched class: 28:16:08 Tranquilizers

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ARIPIPRAZOLE, ASENAPINE, BREXPIPRAZOLE, FLUPENTIXOL DECANOATE, FLUPENTIXOL DIHYDROCHLORIDE, PALIPERIDONE, PALIPERIDONE PALMITATE, PERICYAZINE, PIMOZIDE, ZIPRASIDONE HCL MONOHYDRATE, ZUCLOPENTHIXOL DECANOATE, ZUCLOPENTHIXOL DIHYDROCHLORIDE Some products covered without a code (check the product listing): ALPRAZOLAM, BROMAZEPAM, CHLORDIAZEPOXIDE, CHLORPROMAZINE, CLORAZEPATE DIPOTASSIUM, DIAZEPAM, FLUPHENAZINE HCL, HALOPERIDOL, HALOPERIDOL DECANOATE, LORAZEPAM, LOXAPINE SUCCINATE, LURASIDONE HYDROCHLORIDE, OLANZAPINE, OXAZEPAM, PERPHENAZINE, PROCHLORPERAZINE, QUETIAPINE, RISPERIDONE, TRIFLUOPERAZINE 28:16:08 Tranquilizers

ARIPIPRAZOLE

· 70 products · General benefit · strengths: 720mg/2.4mL, 960mg/3.2mL, 300mg/Vial, 400mg/Vial, 2mg, 5mg, 10mg, 15mg, 20mg, 30mg · Inj Sol-Pref Syr, Prolong-Rel Inj Pd-Vial Pk, Tab

BREXPIPRAZOLE

· 6 products · General benefit · strengths: 0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg · Tab

PALIPERIDONE

· 3 products · General benefit · strengths: 3mg, 6mg, 9mg · ER Tab

PALIPERIDONE PALMITATE

· 8 products · General benefit · strengths: 50mg, 75mg, 100mg, 150mg, 175mg/0.875mL, 263mg/1.315mL, 350mg/1.75mL, 525mg/2.625mL · Inj Pref Syr, Inj Susp-Pref Syr

RISPERIDONE

· 82 products · Listed, not a benefit (12), General benefit (70) · strengths: 1mg/mL, 0.5mg, 1mg, 2mg, 3mg, 4mg, 25mg, 37.5mg, 50mg, 0.25mg · O/L, Orally Disintegrating Tab, Pd for Inj-Vial Pk, Tab

ASENAPINE

· 2 products · General benefit · strengths: 5mg, 10mg · SL Tab

CHLORPROMAZINE

· 6 products · General benefit (3), Listed, not a benefit (3) · strengths: 25mg, 50mg, 100mg · Tab

FLUPENTIXOL DECANOATE

· 2 products · General benefit · strengths: 20mg/mL, 100mg/mL · Inj Sol-1mL Amp Pk

FLUPENTIXOL DIHYDROCHLORIDE

· 2 products · General benefit · strengths: 0.5mg, 3mg · Tab

FLUPHENAZINE HCL

· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 1mg, 2mg, 5mg · Tab

HALOPERIDOL

· 14 products · Listed, not a benefit (7), General benefit (7) · strengths: 5mg/mL, 0.5mg, 1mg, 2mg, 5mg, 10mg, 20mg · Inj Sol-1mL Pk, Tab

LOXAPINE SUCCINATE

· 8 products · Listed, not a benefit (4), General benefit (4) · strengths: 5mg, 10mg, 25mg, 50mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:16:08 and 21 more
Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:08 Opiate Agonists, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:04 Antidepressants, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: manic or mixed episodes associated with bipolar i disorder, schizophrenia
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: ASENAPINE, BREXPIPRAZOLE, PALIPERIDONE PALMITATE ASENAPINE · General benefit INDICATIONS AND CLINICAL USE Adults: Schizophrenia SAPHRIS® (asenapine) sublingual tablet is indicated for the treatment of schizophrenia. PM: https://pdf.hres.ca/dpd_pm/00060860.PDF; date April 27, 2021; DIN 02374803; fetched 2026-09-10 Product monograph Bipolar Disorder SAPHRIS® is indicated for the acute treatment of manic or mixed episodes associated with bipolar I disorder. PM: https://pdf.hres.ca/dpd_pm/00060860.PDF; date April 27, 2021; DIN 02374803; fetched 2026-09-10 Product monograph BREXPIPRAZOLE · General benefit 1 INDICATIONS REXULTI (brexpiprazole) is indicated for: • treatment of schizophrenia in adults. PM: https://pdf.hres.ca/dpd_pm/00074327.PDF; date February 16, 2017; DIN 02461749; fetched 2026-09-10 Product monograph • treatment of schizophrenia in adults. In clinical trials, REXULTI was found to significantly improve both positive and negative symptoms. PM: https://pdf.hres.ca/dpd_pm/00074327.PDF; date February 16, 2017; DIN 02461749; fetched 2026-09-10 Product monograph PALIPERIDONE PALMITATE · General benefit 1 INDICATIONS Adults INVEGA SUSTENNA® (paliperidone palmitate prolonged-release injectable suspension) is indicated for: • the treatment of schizophrenia. PM: https://pdf.hres.ca/dpd_pm/00072646.PDF; date June 30, 2010; DIN 02354217; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS Schizophrenia VRAYLAR (cariprazine) is indicated for: • the treatment of schizophrenia in adults. In controlled clinical trials, VRAYLAR was found to improve both positive and negative symptoms. Bipolar I disorder VRAYLAR is indicated as monotherapy for: • Bipolar Mania: acute management of manic or mixed episodes associated with bipolar I disorder in adults, and • Bipolar Depression: acute management of depressive episodes associated with bipolar I disorder in adults. The efficacy of VRAYLAR for long-term use has not been systematically evaluated in controlled studies for bipolar mania and depression (See 14 CLINICAL TRIALS). The physician who elects to use VRAYLAR for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient. 1.1 Pediatrics Pediatrics (< 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Geriatrics: VRAYLAR is not indicated in elderly patients with dementia. See 3 SERIOUS WARNINGS AND PRECAUTIONS BOX. The safety and efficacy of VRAYLAR have not been systematicall… https://pdf.hres.ca/dpd_pm/00074842.PDF PM date: MAR 06, 2024 Source product: VRAYLAR; DIN 02526794; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.